WASHINGTON — Federal health advisers say there is little-to-no evidence that a popular technique for removing fibroids can be performed without the risk of spreading undetected cancers to other parts of the body.
The panel of Food and Drug Administration (FDA) experts also said Friday that women who do undergo the procedure should sign a written consent form stating they understand the serious risks of laparoscopic power morcellation, in which electronic tools are used to grind tissue and remove it through a small incision in the abdomen.
Surgeons developed the technique as an alternative to traditional surgery, which requires a larger incision that often results in more bleeding and longer hospital stays. The FDA convened a two-day meeting this week after concluding that the risk of accidentally spreading undetected cancer may be far more common than previously thought.
The agency asked its panel of obstetrics and gynecology experts to weigh in on potential methods for minimizing the risk, including using plastic specimen bags to catch bits of shredded tissue. Some surgeons already use that technique, but panelists said it is based on “intuition.”
- Female tiger killed by mating partner at Sacramento Zoo
- Job cuts planned as Boeing hunkers down to compete with Airbus, consider new plane
- Amid Zika fears, local family shares the reality of microcephaly
- Seahawks sign CFL receiver Jeff Fuller and running back Cameron Marshall
- Nigerian suicide bomber gets cold feet, refuses to kill
Most Read Stories
“There’s no evidence that the bags or any containment devices prevent the outcome we are trying to prevent,” said Dr. Craig Shriver of the Walter Reed Medical Center.
The panel also discussed the difficulties of screening women for a rare form of uterine cancer, leiomyosarcoma, ahead of the procedure. Imaging techniques are often unable to distinguish between the cancers and normal fibroids. And while there are some common risk factors, panelists said they are not reliable.
The FDA takes the opinions of its panelists into consideration when it makes decisions on medical devices and other treatments. The agency has not set a timeline for taking action on power morcellators.
Doctors have long acknowledged the risk of accidentally spreading undetected cancer with such electronic shredding tools. But in April the FDA said doctors should halt use of the devices for fibroid treatments after agency scientists calculated the risk of cancer spread was greater than previously thought: as many as 1 in 350 women instead of the previous 1 in 7,000.